The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Experimental research

MAHOROBA™: Tacrolimus eluting coronary stent


1. Department of Interventional Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands; 2. Department of Experimental Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands; 3. Kaneka Corporation, Osaka, Japan

Kaneka’s coronary stent, MAHOROBA™, is a new drug eluting stent (DES), which combines a thin, flexible cobalt-chromium (CoCr) metal stent platform coated with a biodegradable polymer including the pharmaceutical agent tacrolimus. The device has been designed and developed to inhibit the growth of neointimal hyperplasia and avoid interference with the vascular healing response.


The advent of DES has revolutionised the practice of interventional cardiology by inhibiting the development of neointimal hyperplasia and thereby reducing the rates of restenosis and repeat revascularisation as compared to bare metal stents (BMS)1-4. After the first approval of ...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

Read next article
The CardioMind coronary stent delivery system: stent delivery on a .014" guidewire platform